Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2000

View Archived Issues

BioCryst strengthens drug candidate pipeline

Proteasome inhibitor PS-519 protective in cerebral ischemia model

GABA-B antagonist CGP-36742 promnestic in epilepsy model

NIH to conduct trials of potential new transplant therapy for diabetes

Incyte and Elitra establish antimicrobial genomics alliance

FDA approves Glucovance for treatment of type 2 diabetes

CRF1 receptor antagonist displays safety and efficacy in clinical trial

Research advances the use of transgenic plants to deliver vaccines

CGS-21680 promising agent for myocardial perfusion imaging

PR-000350 shows promise in improving efficacy of radiation therapy

Allovectin-7 phase I/II data released

Aventis seeks approval of Dynepo in U.S. and Europe

Icos and Array BioPharma expand collaboration

AMBI licenses nisin and lysostaphin to Biosynexus

Ginkgo biloba extract shows promise as treatment for dementia

Novel arylpiperazines assessed as uroselective agents for BPH

Once-daily postoperative dosing approved for Fragmin

Forest licenses dexloxiglumide from Rotta for treatment of IBS

New serine protease inhibitors useful for thromboembolic disorders

New serine protease inhibitors useful for treating cancer

New HIV integrase inhibitors under study at Merck & Co.

DNA topoisomerase II inhibitors under study at Lafon

New alpha4-integrin antagonists useful for asthma, etc.

New IL-5 inhibitors under development at Janssen

New antimicrobial agents under development at SmithKline Beecham

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...